JPAD-Journal of Prevention of Alzheimers Disease

Article	Citations
Erratum to: Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats	781
Ten Years after the National Alzheimer's Plan: Dementia Remains a Hidden Syndrome in France	455
Validation of the CogDrisk Instrument as Predictive of Dementia in Four General Community-Dwelling Populations	115
On the 2024 Alzheimer's Association Criteria: Still Not Ready for Clinical Use	108
Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation	99
Estimation of the value-based price of a blood test for Alzheimer’s disease pathology in primary and specialty care in the U.S.	92
Herpes zoster and dementia : more evidences for a causal link	82
Maximizing the Utility of Alzheimer's Disease Trial Data: Sharing of Baseline A4 and LEARN Data	72
Evaluation of Memantine in AAV-AD Rat: A Model of Late-Onset Alzheimer's Disease Predementia	62
Effects of Non-Invasive Brain Stimulation on Alzheimer's Disease	58
Gene and genetic therapies in Alzheimer’s disease and other dementias	54
Informing etiological heterogeneity of mild cognitive impairment and risk for progression to dementia with plasma p-tau217	50
Neuroprotective Effects of IVIG against Alzheimer's Disease via Regulation of Antigen Processing and Presentation by MHC Class I Molecules in 3xTg-AD Mice	47
Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer’s disease	44
‘Time Saved' As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings	42
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease	42
The Geras Solutions Cognitive Test for Assessing Cognitive Impairment: Normative Data from a Population-Based Cohort	40
Informal care for people with dementia in Europe	40
Introduction to the Special Issue on the A4 Study	39
AMBAR: A Therapeutical Approach for Alzheimer's Disease Patients Regardless of Amyloid Status	39
LMTK2 and CRB1 are two novel risk genes for Alzheimer's disease in Han Chinese	33
A systematic review of targeted dementia risk reduction interventions in middle-aged adults in Primary Care	33
Association between Comorbidity Indices and Functional Autonomy in Individuals with Cognitive Impairment: A Systematic Review	31
Projected Savings to Canadian Provincial Budgets from Reduced Long-Term Care Home Utilization Due to a Disease-Modifying Alzheimer's Treatment	29
Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer's Disease from Frontotemporal Lobar Degeneration	28

The Shape Trail Test Is Sensitive in Differentiating Older Adults with Mild Cognitive Impairment: A Culture-neutral Five-minute Test	28
Brain health services for the secondary prevention of cognitive impairment and dementia: Opportunities, challenges, and the business case for existing and future facilities	27
Independent and Joint Associations of Socioeconomic Status and Lifestyle behaviors with Cognitive Impairment among Elderly Chinese Population	27
Metformin in the Prevention of Alzheimer's Disease and Alzheimer's Disease Related Dementias	26
Phase 1 Studies of the Anti-Tau Monoclonal Antibody JNJ-63733657 in Healthy Participants and Participants with Alzheimer's Disease	24
Disparities in out-of-pocket costs for disease-modifying therapy under Japan's universal health insurance system	24
Donanemab: Appropriate use recommendations	23
The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6	22
Longitudinal Evolution of Financial Capacity and Cerebral Tau and Amyloid Burden in Older Adults with Normal Cognition or Mild Cognitive Impairment	22
In Vivo Detection of Changes Related to Cortical Columnar Organization and Neuroinflammation Across the AD Continuum	22
Disease-Modifying Antirheumatic Drugs and Dementia Prevention: A Systematic Review of Observational Evidence in Rheumatoid Arthritis	22
Cardiovascular Risk Scales Association with Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cardiovascular Low Cardiovascular Risk Regions	22
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease	22
Are Population-Level Approaches to Dementia Risk Reduction Under-Researched? A Rapid Review of the Dementia Prevention Literature	21
The Therapeutic Effects of Noninvasive Brain Stimulation Combined with Cognitive Training in Elders with Alzheimer's Disease or Amnesic Mild Cognitive Impairment	21
Erratum to: Alzheimer's Disease Composite Score: a Post-Hoc Analysis Using Data from the LipiDiDiet Trial in Prodromal Alzheimer's Disease	21
Preclinical detection of Alzheimer’s disease pathology using conceptual discrimination abilities	20
A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer’s disease	20
Editorial Board	20
The role of Tau, amyloid-β and neuroinflammation in the association between cognition and white matter hyperintensities in a southeast Asian cohort	19
Cardiovascular-kidney-metabolic syndrome and incidence of dementia among older adults	19
Differential effects of soluble and plaque amyloid on late-life depression: The moderating role of tau pathology	19
New-generation antidiabetic medications and dementia risk in older adults with type 2 diabetes: A retrospective cohort study	18
Novel Blood-Based Biomarkers and Disease Modifying Therapies for Alzheimer's Disease. Are We Ready for the New Era?	18
Longitudinal Impacts of Precision Greenness on Alzheimer's Disease	18
Erratum to: Education as Risk Factor of Mild Cognitive Impairment: The Link to the Gut Microbiome	18
Programmed Death of Microglia in Alzheimer's Disease: Autophagy, Ferroptosis, and Pyroptosis	18
Donanemab in early symptomatic Alzheimer’s disease: results from the TRAILBLAZER-ALZ 2 long-term extension	17
Association of Vascular Endothelial Growth Factor Levels with Risk of Alzheimer's Disease: A Systematic Review and Meta-Analysis	17
Global Burden of Dementia Death from 1990 to 2019, with Projections to 2050: An Analysis of 2019 Global Burden of Disease Study	17
Adherence to an anti-inflammatory diet is associated with lower Alzheimer’s disease mortality: A modifiable risk factor in a national cohort	17
Treatments for Alzheimer’s and the declaration of Helsinki	17
16th Clinical Trials on Alzheimer's Disease (CTAD) Boston, MA (USA) October 24–27, 2023: Posters	17
Trajectories of muscle strength and physical performance preceding dementia in older US and European populations	17
Validation of an Ultra-Sensitive Method for Quantitation of Phospho-Tau 217 (pTau217) in Human Plasma, Serum, and CSF using the ALZpath pTau217 Assay on the Quanterix HD-X Platform	16
The Causal Relationship between Genetically Predicted Biological Aging, Alzheimer's Disease and Cognitive Function: A Mendelian Randomisation Study	16
Effectiveness of Physical Exercise on Alzheimer's disease. A Systematic Review	16
Blood pressure and Alzheimer’s disease biomarkers in cognitively unimpaired adults: a multicenter study	16
Relationship between Plasma P-Tau217 and Amyloid PET in Racial and Ethnic Underrepresented Groups (RE-URG) Compared with Non RE-URG in LEARN and A4	16
Reply to Letter to the Editor: “Early-Onset Type 2 Diabetes and Risk of Dementia”	15
Where Do We Go from Here?	15
Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy	15
Associations of early-onset coronary heart disease and genetic susceptibility with incident dementia and white matter hyperintensity: A prospective cohort study	14
Serum Tau-A and Tau-C Levels and Their Association with Cognitive Impairment and Dementia Progression in a Memory Clinic Derived Cohort	14
Corrigendum to “17th Clinical Trials on Alzheimer's Disease (CTAD) Madrid, Spain, October 29 - November 1, 2024: Symposia, Oral Communications” [J Prev Alzheimers Dis 2025;12(1S):100043].	14
A Cholecystokinin Analogue Ameliorates Cognitive Deficits and Regulates Mitochondrial Dynamics via the AMPK/Drp1 Pathway in APP/PS1 Mice	14
Identifying the optimal combinations of modifiable dementia risk factors to target in multidomain intervention – Three-year longitudinal findings from the Canadian longitudinal study on aging	14
Clarifying what BP Predicts: Commentary on CSF Aβ42/40, p-tau181, and centiloid in unimpaired populations	14
Basal forebrain global functional connectivity is preserved in asymptomatic presenilin-1 E280A mutation carriers: Results from the Colombia cohort	14
Erratum to: Digital Clock Drawing as an Alzheimer's Disease Susceptibility Biomarker: Associations with Genetic Risk Score and APOE in Older Adults	14

Lower baseline amyloid beta burden is associated with greater percent of amyloid beta positron emission tomography reduction and better clinical outcomes in the aducanumab Phase 3 trials ENGAGE and EM	14
Data-Driven Thresholding Statistically Biases ATN Profiling across Cohort Datasets	14
Association of Blood MicroRNA Expression and Polymorphisms with Cognitive and Biomarker Changes in Older Adults	13
Development of a Mobile-First Registry to Recruit Healthy Volunteers and Members of Underrepresented Communities for Alzheimer's Disease Prevention Studies	13
Modulatory Effect of Blood LDL Cholesterol on the Association between Cerebral Aβ and Tau Deposition in Older Adults	13
Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabece	13
Reproductive Markers in Alzheimer's Disease Progression: The Framingham Heart Study	13
Representation of Racial and Ethnic Minority Populations in Dementia Prevention Trials: A Systematic Review	13
Plasma amyloid-β precursor protein 669–711/amyloid-β1–42 ratio is associated with cognition in Alzheimer's disease	13
Brain photobiomodulation: a potential treatment in Alzheimer’s and Parkinson’s diseases	12
Bacillus Calmette-Guerin (BCG) Vaccine Impact on Dementia Risk in Bladder Cancer Patients: A Systematic Review and Meta-Analysis	12
The Association between Sugar-Sweetened Beverages and Cognitive Function in Middle-Aged and Older People: A Meta-Analysis	12
Usefulness of Cerebrospinal Fluid Alzheimer's disease biomarkers in older patients: Evidence from a national multicenter prospective study	12
Disclosure of Alzheimer’s disease blood-based biomarker results in a primary care setting: Opportunities and challenges	12
Cardiovascular health, genetic predisposition, and dementia risk among atherosclerotic cardiovascular disease patients	12
17th Clinical Trials on Alzheimer's Disease (CTAD) Madrid, Spain, October 29 - November 1, 2024	12
Long-term cumulative physical activity associated with less cognitive decline: Evidence from a 16-year cohort study	12
Current Themes and Controversies in the Alzheimer's Disease Field: Looking Ahead to the CTAD Meeting in San Francisco, November 29–December 2 2022	12
Feasibility and acceptability of remote APOE-genotyping among research volunteers of an online recruitment registry (The Dutch Brain Research Registry)	12
The differential effect of strength, cognitive and aerobic training combinations on cognitive performance and functional abilities in elderly with cognitive decline: The Fit4Alz project	12
Interest in and Experience with Genetic Testing for Late-Onset Medical Conditions: Results from the National Poll on Healthy Aging	12
Chinese Preclinical Alzheimer's Disease Study (C-PAS): Design and Challenge from PET Acceptance	12
Structural equation modeling confirms interaction of Alzheimer’s disease and vascular disease in hippocampal injury	12
Identifying synergistic combinations of repurposed treatments for Alzheimer’s Disease	12
Serum BDNF and progression to MCI in cognitively normal older adults A prospective cohort study	12
Early detection of Alzheimer’s disease using small RNAs. Results from the EPAD cohort	12
Feasibility of computerized motor, cognitive and speech tests in the home: Analysis of TAS Test in 2,300 older adults	12
The Effects of Subjective Cognitive Decline on APOE Genotype Disclosure in the Butler Hospital Alzheimer's Prevention Registry	11
The Scottish Brain Health Service Model: Rationale and Scientific Basis for a National Care Pathway of Brain Health Services in Scotland	11
Editorial Board	11
The Clinical Trials Alzheimer's Disease (CTAD) Meeting in San Francisco, Fall 2022, Will Be a Very Exciting Event!	11
Relationships of Hypnotics with Incident Dementia and Alzheimer's Disease: A Longitudinal Study and Meta-Analysis	11
Association of Preeclampsia with Incident Dementia and Alzheimer's Disease among Women in the Framingham Offspring Study	11
The ‘Aducanumab Story': Will the Last Chapter Spell the End of the ‘Amyloid Hypothesis' or Mark a New Beginning?	11
Mechanisms Underlying Non-Pharmacological Dementia Prevention Strategies: A Translational Perspective	11
“Back to Braak”: Role of Nucleus Reuniens and Subcortical Pathways in Alzheimer's Disease Progression	11
Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer's Treatments with Different Duration and Route of Administration	11
Public Policy Should Foster Alzheimer's Treatment Availability: Comment on the Draft US Medicare Decision to Limit Payment for Aducanumab (Aduhelm™) to Patients Participating in Clinical Trials	10
Decreased Gray—White Matter Contrast of [11C]-PiB Uptake in Cognitively Unimpaired Subjects with Severe Obstructive Sleep Apnea	10
Fingolimod ameliorates amyloid deposition and neurodegeneration in APP/PS1 mouse model of Alzheimer's disease	10
Consistency between Treatment Effects on Clinical and Brain Atrophy Outcomes in Alzheimer's Disease Trials	10
Universal Prevention of Dementia in Italy: A Document Analysis of the 21 Italian Regional Prevention Plans	10
First Experiences with Amyloid-Related Imaging Abnormalities — Yet without Imaging that Can Rule Out Cerebral Injury or Monitor Efficacy of Recommended Management	10
Patient eligibility for amyloid-targeting immunotherapies in Alzheimer's disease	10
Reducing the Effects of Ageing on Cognition with Therapeutic Intervention of an Oral Multi-Nutrient: The REACTION Pilot Trial Study Design	10
A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer's Disease	10
Polyunsaturated fatty acids, APOE genotypes, and dementia incidence and mortality among hypertensive adults	10
Tackling a Major Deficiency of Diversity in Alzheimer's Disease Therapeutic Trials: An CTAD Task Force Report	10
Multiomics Blood-Based Biomarkers Predict Alzheimer's Predementia with High Specificity in a Multicentric Cohort Study	10
Diagnostic Accuracy of Plasma p-tau217 for Detecting Pathological Cerebrospinal Fluid Changes in Cognitively Unimpaired Subjects Using the Lumipulse Platform	10
Embryo Selection for a Carrier of an Early-Onset Alzheimer's Disease-Associated Mutation in the PSEN1 Gene	10
Response to “Multi-omics analysis of druggable genes to facilitate Alzheimer's disease therapy: A multi-cohort machine learning study”	10
Association of Multi-Domain Factors with Cognition in the UK Biobank Study	10
Add-on combination therapy with monoclonal antibodies: Implications for drug development	10
Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats	10
Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force	10
Exploring the Association between Amyloid-β and Memory Markers for Alzheimer's Disease in Cognitively Unimpaired Older Adults	9
The role of serum vitamins in mediating the effect of neurodegenerative diseases on subcortical brain volume	9
Prevalence and co-occurrence of dementia risk factors in Denmark: A nationwide study	9
The Dawn of a New Era of Alzheimer's Research and Drug Development	9
Comparative efficacy of cognitive training modalities in cognitive impairment: A systematic review and network meta-analysis	9
Flavonoid-Rich Fruit Intake in Midlife and Late-Life and Associations with Risk of Dementia: The Framingham Heart Study	9
Content	9
Stress internalization is a top risk for age-associated cognitive decline among older Chinese in the U.S	9
Assessing the causal role of lipid metabolites in Alzheimer's disease: A mendelian randomization study	9
Comment on “Multi-omics analysis of druggable genes to facilitate Alzheimer's disease therapy: A multi-cohort machine learning study”	9
Latent cognitive profiles and their associations with instrumental activities of daily living among older adults without dementia: A United States national cross-sectional study	9
Prevention of Alzheimer's Disease and Cognitive Decline with Diet & Lifestyle: Proceedings of the A. G. Leventis Foundation Conference	9
The Future is Now: Advancing Blood-Based Markers	9
Left Frontoparietal Control Network Connectivity Moderates the Effect of Amyloid on Cognitive Decline in Preclinical Alzheimer's Disease: The A4 Study	9
«Compounded Interest» in Alzheimer's Disease: Do New Amyloid-Targeting Treatments Justify Their Use	9
Associations and Potential Multiple Mechanisms between Subjective Hearing Loss and Cognitive Impairment	9
Reply to: Mitochondrial dysfunction as the missing link between circadian syndrome and dementia	9
Higher Cognitive Reserve Is Beneficial for Cognitive Performance Via Various Locus Coeruleus Functional Pathways in the Pre-Dementia Stage of Alzheimer's Disease	8
Alzheimer's Disease Biomarker Decision-Making among Patients with Mild Cognitive Impairment and Their Care Partners	8
Visual Event-Related Potentials under External Emotional Stimuli as Early Signs for Mild Cognitive Impairment	8
Microglial activation states and their implications for Alzheimer's Disease	8
Early-Onset Type 2 Diabetes and Risk of Dementia	8
Temporal associations of neuropsychiatric symptoms, demographics and amyloid with subsequent tau burden in older adults	8
Preventing dementia in Italy: Estimations of modifiable risk factors and public health implications	8

The role for artificial intelligence in identifying combination therapies for Alzheimer’s disease	8
Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylat	8
Phase 1/2a Intravenous and Subcutaneous Oligomer-Specific Antibody KHK6640 in Mild to Moderate Alzheimer's Disease	8
Motor abilities and cognitive performance in Latinos with autosomal dominant Alzheimer's disease	8
A novel early imaging biomarker for glymphatic function: Cerebral cortical arterial pulsatility index from 2-Minute phase-contrast MRI	8
Unveiling Potential Biomarkers in Cerebrospinal Fluid for Amyloid Pathological Positivity in Non-Demented Individuals	8
Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer's and Parkinson's Patients	8
Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies	8
At a Glance: An Update on Neuroimaging and Retinal Imaging in Alzheimer's Disease and Related Research	8
APOE ε4-related differences in brain structure, function, and connectivity at midlife: A scoping review	8
Lifestyle factors and plasma biomarkers of Alzheimer's disease: A narrative review	7
Baseline habitual dietary nitrate intake and Alzheimer's Disease related neuroimaging biomarkers in the Australian Imaging, Biomarkers and Lifestyle study of ageing	7
Associations of ischemic heart disease with brain glymphatic MRI indices and risk of Alzheimer's disease	7
Opposite causal effects of type 2 diabetes and metformin on Alzheimer's disease	7
Corrigendum to Enhancing dementia prediction: A 19-year validation of the CAIDE risk score with insulin resistance and APOE ε4 integration in a population-based cohort	7
Current status and future directions for the diagnosis and management of mild cognitive impairment in Southeast Asia: A SEACURE consensus paper	7
Anti-Hypertensive Drugs Moderate the Relationship of Blood Pressure with Alzheimer's Pathologies and Neurodegenerative Markers in Non-Demented Hypertensive Older Adults	7
Who Benefited the Most? Effectiveness of a Lifestyle Intervention Against Cognitive Decline in Older Women and Men – Secondary Analysis of the AgeWell.de-trial	7
Magnetic Resonance Imaging-Negative Cerebral Amyloid Angiopathy: Cerebrospinal Fluid Amyloid-β42 over Amyloid Positron Emission Tomography	7
Economic Impact of Progression from Mild Cognitive Impairment to Alzheimer Disease in the United States	7
High Intake of Dietary Cholesterol Decreases the Risk of All-Cause Dementia and AD Dementia: A Results from Framingham Offspring Cohort	7
ASURE Clinical Trial Protocol: A Randomized, Placebo-Controlled, Proof-of-Concept Study Aiming to Evaluate Safety and Target Engagement following Administration of TW001 in Early Alzheimer's Disease P	7
Brain health PRO/santé cerveau PRO: The development of a web-based program for dementia literacy and risk factor reduction	7
Adult Renal Dysfunction and Risk of Dementia or Cognitive Decline: Brain-Kidney Axis Hypothesis Based on a Systematic Review and Meta-Analysis	7
Genetic predisposition to high circulating levels of interleukin 6 and risk for Alzheimer's disease. Discovery and replication	7
Mendelian Randomization Analysis Reveals Causal Factors behind Alzheimer's Disease Risk: Evidence, Opportunities, and Challenges	7
Implications of Emerging Uses of Genetic Testing for Alzheimer's Disease	7
A Conformational Variant of p53 (U-p53AZ) as Blood-Based Biomarker for the Prediction of the Onset of Symptomatic Alzheimer's Disease	7
Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial	7
Appropriate Use Recommendations for Lecanemab	7
Association between Resting Heart Rate and Machine Learning-Based Brain Age in Middle- and Older-Age	7
China Initiative for Multi-Domain Intervention (CHINA-IN-MUDI) to Prevent Cognitive Decline: Study Design and Progress	7
Development and Concurrent Validity of the Short-Form CogDrisk Dementia Risk Assessment Tool	7
Everyday Functioning and Entorhinal and Inferior Temporal Tau Burden in Cognitively Normal Older Adults	7
Association of the difference between cystatin C- and creatinine-based estimated glomerular filtration rate with cerebral small vessel disease: A large prospective cohort study	7
Corrigendum to “Multiomics Blood-Based Biomarkers Predict Alzheimer's Predementia with High Specificity in a Multicentric Cohort Study” [The Journal of Prevention of Alzheimer's Disease 2024;11(3):567	6
Semorinemab Pharmacokinetics and The Effect on Plasma Total Tau Pharmacodynamics in Clinical Studies	6
Medical risk factors, ApoE haplotype, and Alzheimer’s disease: a large-scale analysis	6
Baseline Findings of PreventE4: A Double-Blind Placebo Controlled Clinical Trial Testing High Dose DHA in APOE4 Carriers before the Onset of Dementia	6
Unsupervised Performance of the CogState Brief Battery in the Brain Health Registry: Implications for Detecting Cognitive Decline	6
Update to: Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease	6
The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report	6
Sample size estimates for biomarker-based outcome measures in clinical trials in autosomal dominant Alzheimer's disease	6
Can non-pharmacological interventions change levels of neurofilament light in older adults at risk of dementia? A secondary analysis of the SCD-Well randomized clinical trial	6
Editorial Board	6
Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer's Disease	6
“Time Saved” Calculations to Improve Decision-Making in Progressive Disease Studies	6
Hypnotics and Incident Dementia: A Risk Assessment	6
Association between Family Household Income and Cognitive Resilience among Older US Adults: A Cross-Sectional Study	6
Effects of Vitamin D3 Combined with Folic Acid on Domain and Specific Cognitive Function among Patients with Mild Cognitive Impairment: A Randomized Clinical Trial	6
Continuous Associations between Remote Self-Administered Cognitive Measures and Imaging Biomarkers of Alzheimer's Disease	6
Adjudicating Mild Cognitive Impairment Due to Alzheimer's Disease as a Novel Endpoint Event in the TOMMORROW Prevention Clinical Trial	6
Cytomegalovirus Infection and Alzheimer's Disease: A Meta-Analysis	6
Alzheimer's Disease Prevention Health Coaching	6
Plasma p-tau217 predicting brain-wide tau accumulation in preclinical AD	6
Dietary Cholesterol and Dementia Risk	6
Eligibility for donanemab trial in a population-based study of cognitive aging	6
Multi-omics analysis of druggable genes to facilitate Alzheimer's disease therapy: A multi-cohort machine learning study	6
Multimorbidity and risk of dementia: A systematic review and meta-analysis of longitudinal cohort studies	6
Gender-Specific Design and Effectiveness of Non-Pharmacological Interventions against Cognitive Decline — Systematic Review and Meta-Analysis of Randomized Controlled Trials	6
A Hierarchical Bayesian Latent Class Model for the Diagnostic Performance of Mini-Mental State Examination and Montreal Cognitive Assessment in Screening Mild Cognitive Impairment Due to Alzheimer's D	6
Therapeutic Targets for Alzheimer's Disease: Amyloid Vs. Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task Force Report	6
Mendelian Randomization Analysis to Assess Whether Magnetic Resonance Imaging Signs of Cerebral Small Vessel Disease Can Cause Cognitive Decline and Dementia	6
Expectancy Does Not Predict 18-month Treatment Outcomes with Cognitive Training in Mild Cognitive Impairment	6
Content	6
Mitochondrial dysfunction as the missing link between circadian syndrome and dementia	6
Heightened Prevalence of Common Hospital-Treated Infections Preceding Dementia Diagnosis with Accelerated Dementia Onset after Influenza	6
The Room Where It Happens: Clinician Reflections on Returning Preclinical Alzheimer's Biomarker Results to Research Participants	5
Are We There Yet (and How Do We Get There…)?	5
The impact of hypertension prevention and modification on dementia burden: A systematic review of economic studies	5
Pharmacological Inventions for Alzheimer Treatment in the United States of America: A Revision Patent from 2010–2020	5
Association between Neuropsychological Performance and CSF Profile in Subjective Cognitive Decline: Towards the Diagnosis of Preclinical AD	5
The AlzMatch Pilot Study - Feasibility of Remote Blood Collection of Plasma Biomarkers for Preclinical Alzheimer's Disease Trials	5
Behaviour change techniques used in interventions targeting dementia risk factors amongst older adults in rural and remote areas: A systematic review and meta-analysis	5
Microstructural white matter injury contributes to cognitive decline: Besides amyloid and tau	5
Roles of TREM2 in the Pathological Mechanism and the Therapeutic Strategies of Alzheimer's Disease	5
Is “Pre-Preclinical AD” Helpful to the EU/US CTAD Task Force?	5
What Are the Remaining Challenges before Blood-Based Biomarkers for Alzheimer's Disease Can Be Used in Clinical Practice?	5
The Effects of Different Exercise Interventions on Patients with Subjective Cognitive Decline: A Systematic Review and Network Meta-Analysis	5
A Genetic Validation of the Neurodegeneration Biomarkers Tau-A and Tau-C - A Mendelian Randomization Study	5
Association between 9p21–23 Locus and Frailty in a Community-Dwelling Greek Population: Results from the Hellenic Longitudinal Investigation of Ageing and Diet	5
Influence of APOE ε4 on performance of CSF biomarkers in differentiating clinical Alzheimer's disease	5
Organ-specific proteomic aging and cognitive performance: Implications for risk prediction of Alzheimer’s disease and related dementias in older adults	5
Protocol of a Phase II Randomized, Multi-Center, Double-Blind, Placebo-Controlled Trial of S-Adenosyl Methionine in Participants with Mild Cognitive Impairment or Dementia Due to Alzheimer's Disease	5
MemScreen: A smartphone application for detection of mild cognitive impairment: A validation study	5
Anxiety and Depressive Symptoms and Cortical Amyloid-β Burden in Cognitively Unimpaired Older Adults	5
A Large Retrospective Cohort Study on the Risk of Alzheimer's Disease and Related Dementias in Association with Vascular Diseases and Cancer Therapy in Men with Prostate Cancer	5
Periodontal Disease and Alzheimer's: Insights from a Systematic Literature Network Analysis	5
Association between Longitudinal Cerebrospinal Fluid Alzheimer's Biomarkers and the Lifestyle for Brain Health (LIBRA) Index: Findings from the European Prevention of Alzheimer's Dementia Cohort Study	5
Harnessing combination therapy: Current treatments, recent advancements, and future directions in Alzheimer's disease	5
The role of Aβ in Alzheimer's Disease as an Evolutionary Outcome of Optimized Innate Immune Defense	5
Editorial Board	5
Tau Pathologies Mediate the Associations of Vascular Risk Burden with Cognitive Impairments in Non-demented Elders: The CABLE Study	5
Distinct CSF α-synuclein aggregation profiles associated with Alzheimer's disease phenotypes and MCI-to-AD conversion	5
Fructose Consumption is Associated with a Higher Risk of Dementia and Alzheimer's Disease: A Prospective Cohort Study	5